47 results
Keyword Pritorplus Remove keyword
-
List item
Human medicine European public assessment report (EPAR): PritorPlus
telmisartan, hydrochlorothiazide, Hypertension
Date of authorisation: 22/04/2002, Revision: 35, Authorised, Last updated: 07/07/2020PritorPlus Hypertension … assessment report (EPAR) for PritorPlus. It explains how the Committee … the conditions of use for PritorPlus. What is PritorPlus? PritorPlus is a medicine that contains … -
List item
Referral: Renin-angiotensin-system (RAS)-acting agents
captopril, imidapril, zofenopril, candesartan, delapril, telmisartan, aliskiren, moexipril, enalapril, valsartan, fosinopril, irbesartan, perindopril, quinapril, ramipril, eprosartan, olmesartan, trandolapril, losartan, azilsartan, lisinopril, spirapril, benazepril, cilazapril, associated names: Tolucombi, Telmisartan Teva, Telmisartan Teva Pharma, Tolura, Onduarp, Twynsta, Actelsar HCT, Kinzalkomb, MicardisPlus, PritorPlus, Copalia HCT, Dafiro HCT, Exforge HCT, Rasilamlo, Rasilez, Rasilez HCT, Rasitrio, Edarbi, Ipreziv, Aprovel, Ifirmasta (previously Irbesartan Krka), Irbesartan Teva, Irbesartan Zentiva (previously Irbesartan Winthrop), Karvea, Sabervel, CoAprovel, Ifirmacombi, Irbesartan/Hydrochlorothiazide Teva, Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), Karvezide, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Micardis, Pritor, Telmisartan Actavis, Article 31 referrals
Status: European Commission final decision, opinion/position date: 22/05/2014, EC decision date: 04/09/2014, Last updated: 08/10/2014HCT Kinzalkomb MicardisPlus PritorPlus Copalia HCT Dafiro HCT Exforge … HCT Kinzalkomb MicardisPlus PritorPlus Copalia HCT Dafiro HCT Exforge … -
List item
Press release: European Medicines Agency recommendation on use of angiotensin-II-receptor antagonists during pregnancy
Last updated: 24/04/2008medicines: MicardisPlus, PritorPlus and Kinzalkomb. Valsartan … Micardis: EPAR Pritor: EPAR PritorPlus: EPAR Angiotensin-II-receptor … medicines: MicardisPlus, PritorPlus and Kinzalkomb. 5. Valsartan … -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013
PRAC, Last updated: 17/05/2013Osseor: EPAR Pritor: EPAR PritorPlus: EPAR Protelos: EPAR Rasilamlo … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011
CHMP, Last updated: 21/10/2011Osseor: EPAR Pritor: EPAR PritorPlus: EPAR Protelos: EPAR Tandemact … -
List item
Press release: European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive
CHMP, Last updated: 20/10/2011MicardisPlus: EPAR Pritor: EPAR PritorPlus: EPAR Telmisartan Actavis … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013
CHMP, Last updated: 26/04/2013PritorPlus INN telmisartan / hydrochlorothiazide … -
List item
Human medicine European public assessment report (EPAR): MicardisPlus
telmisartan, hydrochlorothiazide, Hypertension
Date of authorisation: 19/04/2002, Revision: 30, Authorised, Last updated: 28/07/2021 -
List item
Human medicine European public assessment report (EPAR): Kinzalkomb
telmisartan, hydrochlorothiazide, Hypertension
Date of authorisation: 19/04/2002, Revision: 37, Authorised, Last updated: 06/07/2021 -
List item
Human medicine European public assessment report (EPAR): Micardis (updated)
telmisartan, Hypertension
Date of authorisation: 16/12/1998, Revision: 25, Authorised, Last updated: 28/09/2021 -
List item
Human medicine European public assessment report (EPAR): Telmisartan Teva (updated)
telmisartan, Hypertension
Date of authorisation: 25/01/2010,
, Revision: 11, Withdrawn, Last updated: 17/09/2021
-
List item
Human medicine European public assessment report (EPAR): Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)
telmisartan, Hypertension
Date of authorisation: 16/12/1998, Revision: 30, Authorised, Last updated: 18/12/2020 -
List item
Human medicine European public assessment report (EPAR): Pritor
telmisartan, Hypertension
Date of authorisation: 11/12/1998, Revision: 29, Authorised, Last updated: 10/12/2020 -
List item
Human medicine European public assessment report (EPAR): Onduarp
telmisartan, Hypertension
Date of authorisation: 24/11/2011, Revision: 2, Withdrawn, Last updated: 02/04/2014 -
List item
Human medicine European public assessment report (EPAR): Sabervel
irbesartan, Hypertension
Date of authorisation: 13/04/2012,, Revision: 2, Withdrawn, Last updated: 29/06/2017
-
List item
Human medicine European public assessment report (EPAR): Imprida
valsartan, amlodipine (as amlodipine besilate), Hypertension
Date of authorisation: 17/01/2007, Revision: 20, Withdrawn, Last updated: 11/05/2017 -
List item
Human medicine European public assessment report (EPAR): Rasilamlo
aliskiren, amlodipine, Hypertension
Date of authorisation: 14/04/2011, Revision: 7, Withdrawn, Last updated: 28/03/2017 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 21/06/2021 to 24/06/2021, Last updated: 11/08/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 17/05/2021 to 20/05/2021, Last updated: 09/07/2021 -
List item
PRAC: Agendas, minutes and highlights
Last updated: 06/08/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 27-30 November 2017
European Medicines Agency, London, UK, from 27/11/2017 to 30/11/2017, Last updated: 27/11/2017 -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 October 2020
Virtual meeting, from 12/10/2020 to 15/10/2020, Last updated: 16/10/2020 -
List item
CHMP: Agendas, minutes and highlights
Last updated: 09/07/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 November 2014
European Medicines Agency, London, UK, from 03/11/2014 to 06/11/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 June 2014
European Medicines Agency, London, UK, from 10/06/2014 to 13/06/2014, Last updated: 13/08/2013